BPT-143 / Bright Peak Therap - LARVOL DELTA

BPT-143: a fully synthetic alpha-dead IL-2 with a best-in-class preclinical pharmacodynamic and efficacy profile supporting first-in-human clinical development (AACR 2022) - "High-dose recombinant IL-2 (aldesleukin) is approved for treatment of advanced melanoma and renal cell carcinoma, however, major limitations restrict its therapeutic use. Both in vivo efficacy studies in murine tumor models as well as PD effects observed in NHP indicate that BPT-143 has a best-in-class profile among “not-alpha” IL-2 compounds currently in development. IND-enabling studies are ongoing and a first in human trial is planned to start in 2022."

P1 data • PK/PD data • Preclinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD4 • CD8 • IL2

Creating next-generation biologics using a novel chemistry platform technology (AACR 2022) - "Enhanced cytokines with differentiated biology developed using this approach can be further elaborated by conjugating to a diverse array of molecules.We first applied our technology platform to identify BPT-143, a rationally designed enhanced IL-2 variant currently in IND-enabling studies...We have prepared a number of ICs including anti-PD-1/IL-2 ICs with various drug-antibody ratio (DAR) and conjugation sites within the antibody. We will provide an overview of the platform technology and present highlights of its application for discovery and development of designer therapeutic cytokines and ICs."

IO biomarker • Oncology • IL2

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "Bright Peak Therapeutics...announced the acceptance of one oral presentation and two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting....Our PD-1/IL-2 ICs induce strong pharmacodynamic effects in vivo, and we are currently optimizing the pharmacological profiles of PD-1-targeted immunocytokines for clinical application....BPT-143 demonstrates the power of our synthetic protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and are exploiting our technology to develop a pipeline of novel designer cytokines and multi-modal immune therapies."

Preclinical • Oncology

Versant Ventures Launches Bright Peak Therapeutics (Businesswire) - "Versant Ventures...announced the debut of Bright Peak Therapeutics...Versant has made a $35 million Series A commitment to the company, which was launched out of the firm’s Ridgeline Therapeutics Discovery Engine based in Basel, Switzerland...The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therapeutics...A pipeline was developed within Versant’s Ridgeline labs in collaboration with ETH Zürich. This included modified versions of IL-2, IL-18 and IL-7 optimized for the desired biology and pharmacokinetic profiles...Bright Peak is currently running IND-enabling studies and has launched scale-up and CMC campaigns on the first IL-2 development candidate with the expectation of entering the clinic within a year."

Commercial • Pipeline update • Oncology